R01DA057197

CART, NEUROHIV, COCAINE ABUSE AND THE MPFC NEURON/ASTROCYTE DYSFUNCTION - ABSTRACT

HIV-associated neurocognitive disorders (HAND) is a significant comorbid condition for people living with HIV/AIDS (PLWH). HAND is associated with HIV-induced neurotoxicity that dysregulates, injures, and in severe cases, causes death of neurons in the key brain regions that regulate neurocognition.

Combined antiretroviral therapy (CART) inhibits active HIV-1 replication; but it has not reduced the prevalence of HAND, as it occurs in 30~50% of PLWH and is expected to increase as PLWH age.

Notably, cocaine (COC) use disorders (CUD) are comorbid with HAND in many cases and worsen it severely. Ironically, although CART is absolutely necessary for treating HIV/AIDS, emerging data point to CART as a potential contributor to HAND through CART-induced neurotoxicity.

This raises key questions regarding if chronic CART contributes to neurological/neurocognitive deficits linked to HAND; and how it alters brain neuron activity in the context of neuroHIV and CUD; both are the focus of this proposal.

Our studies suggest that CART induces neuronal Ca2+ dysregulation in the medial prefrontal cortex (MPFC, a key regulator of neurocognition and addiction), similar to that well-described in neuroHIV and CUD mediated by overactive voltage-gated L-type Ca2+ channels (L-channels) and NMDA receptors (NMDARs).

Dysfunction of MPFC pyramidal neurons is linked to HAND, CUD, and many other neurodegenerative diseases. Thus, we hypothesize that CART-induced MPFC neuronal Ca2+ dysregulation worsens similar dysfunction caused by neuroHIV and COC; and that is reduced by combined antagonism of L-channel/NMDAR overactivation.

We will determine the effects of CART, neuroHIV, and COC on MPFC pyramidal neurons, and elucidate their underlying mechanism. Specifically, we will use three combined rat models of (i) CART (chronic Triumeq, a 1st-line CART regimen consisting of 3 antiretroviral drugs - abacavir, dolutegravir, and lamivudine), (ii) neuroHIV (HIV-1 transgenic rats), and (iii) COC abuse (COC self-administration, COC-SA), to elucidate the long-term effects of CART in vivo on MPFC neuronal activity and their mechanism in the context of neuroHIV and CUD (AIM1).

Define the effects of chronic CART on interactive astrocyte/neuron dysfunction in the MPFC under neuroHIV and CUD conditions (AIM2); and identify the effects of combined antagonism of excessive Ca2+ influx/[Ca2+]in that alleviate neuronal activity and cognitive behavior in the context of neuroHIV/CUD (AIM3).

Further, we will also define HIV/CART/COC-induced neuron/astrocyte dysfunction in post-mortem HIV+ human brains (exploratory AIM) to provide additional support for the principal concept and hypothesis of this proposal.

Together, the proposed research will elucidate the mechanism by which neuroHIV, chronic CART in vivo, and COC-SA, individually and jointly, alter MPFC neuronal activity, and in such process identify the key mechanistic targets that will inform therapeutic intervention for HAND and CUD in the era of CART.

Rush University Medical Center

TO SUPPORT BASIC AND CLINICAL NEUROSCIENCE, BIOMEDICAL, BEHAVIORAL AND SOCIAL SCIENCE, EPIDEMIOLOGIC, HEALTH SERVICES AND HEALTH DISPARITY RESEARCH. TO DEVELOP NEW KNOWLEDGE AND APPROACHES RELATED TO THE PREVENTION, DIAGNOSIS, TREATMENT, ETIOLOGY, AND CONSEQUENCES OF DRUG ABUSE AND ADDICTION, INCLUDING HIV/AIDS. TO SUPPORT RESEARCH TRAINING AND RESEARCH SCIENTIST DEVELOPMENT. TO SUPPORT DISSEMINATION OF RESEARCH FINDINGS. SMALL BUSINESS INNOVATION RESEARCH (SBIR) LEGISLATION IS INTENDED TO EXPAND AND IMPROVE THE SBIR PROGRAMS TO EMPHASIZE AND INCREASE PRIVATE SECTOR COMMERCIALIZATION OF TECHNOLOGY DEVELOPED THROUGH FEDERAL SBIR RESEARCH AND DEVELOPMENT, INCREASE SMALL BUSINESS PARTICIPATION IN FEDERAL RESEARCH AND DEVELOPMENT, AND FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN THE SBIR PROGRAM. THE LEGISLATION INTENDS THAT THE SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAM STIMULATE AND FOSTER SCIENTIFIC AND TECHNOLOGICAL INNOVATION THROUGH COOPERATIVE RESEARCH AND DEVELOPMENT CARRIED OUT BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, FOSTER TECHNOLOGY TRANSFER BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, AND FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION.

93.279 - Drug Abuse and Addiction Research Programs

National Institute on Drug Abuse (NIDA) [HHS - NIH]

Chicago, Illinois 606123833 United States

Single Zip Code

Elucidating the Effects of ART on Neuronal Function in the Context of SUD and HIV (R01 - Clinical Trials Not Allowed) (RFA-DA-22-003)

Amendment Since initial award the total obligations have increased 290% from $786,328 to $3,070,264.